UroGen Pharma’s Promising Trial Results and FDA Progress
Company Announcements

UroGen Pharma’s Promising Trial Results and FDA Progress

An update from Urogen Pharma (URGN) is now available.

UroGen Pharma Ltd. has shared promising results from its Phase 3 ENVISION trial for UGN-102, a potential treatment for low-grade non-muscle invasive bladder cancer. The trial met its primary endpoint, showing a high rate of complete response at three months, with many patients maintaining the response at 12 months. The company is progressing with a New Drug Application to the FDA, eyeing a potential market opportunity exceeding $5 billion for UGN-102. If approved, the treatment could offer a significant alternative to the current standard procedure, potentially improving patient outcomes and quality of life.

For a thorough assessment of URGN stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyUroGen Pharma price target raised to $64 from $60 at H.C. Wainwright
TheFlyUroGen Pharma announces FDA acceptance of new drug application for UGN-102
TheFlyUroGen Pharma initiated with a Buy at EF Hutton
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App